Integrin avb6 Promotes an osteolytic program in cancer cells by upregulating MMP2

Cancer Research

Volumn 74, Issue 5, 2014, Pages 1598-1608

  Dutta, Anindita ^a,b   Li, Jing ^a,d   Lu, Huimin ^a,b   Akech, Jacqueline ^a,d   Pratap, Jitesh ^a,d,h   Wang, Tao ^d   Zerlanko, Brad J ^a,b   Gerald, Thomas J Fitz ^d   Jiang, Zhong ^d   Birbe, Ruth ^a,c   Wixted, John ^a,e   Violette, Shelia M ^f   Stein, Janet L ^a,g   Stein, Gary S ^a,g   Lian, Jane B ^a,g   Languino, Lucia R ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b Departments of Systems Biology   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d Department of Cell Biology ^*  (United States)

^e UNIVERSITY OF MASSACHUSETTS   (United States)

^f BIOGEN   (United States)

^g UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^h RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHAVBETA6 INTEGRIN; ANDROGEN RECEPTOR; GELATINASE A; GELATINASE B; PARATHYROID HORMONE RELATED PROTEIN; SHORT HAIRPIN RNA; AR PROTEIN, HUMAN; INTEGRIN; MMP2 PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR ANTIGEN;

ARTICLE; BONE METASTASIS; CANCER CELL; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; OSTEOLYSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR GROWTH; UPREGULATION; ANIMAL; BONE TUMOR; GENETICS; MALE; METABOLISM; METASTASIS; MOUSE; PROSTATE TUMOR; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; ANTIGENS, NEOPLASM; BONE NEOPLASMS; CELL LINE, TUMOR; HUMANS; INTEGRINS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MICE, SCID; OSTEOLYSIS; PARATHYROID HORMONE-RELATED PROTEIN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TRANSFORMING GROWTH FACTOR BETA1; UP-REGULATION;

EID: 84896514056     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-1796     Document Type: Article

References (49)

1. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002;2:584-93.
2. Morrissey C, Lai JS, Brown LG, Wang YC, Roudier MP, Coleman IM, et al. The expression of osteoclastogenesis-Associated factors and osteoblast response to osteolytic prostate cancer cells. Prostate 2010;70:412-24.
3. Keller ET, Brown J. Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. J Cell Biochem 2004;91: 718-29.
4. Roudier MP, Morrissey C, True LD, Higano CS, Vessella RL, Ott SM. Histopathological assessment of prostate cancer bone osteoblastic metastases. J Urol 2008;180:1154-60.
5. Choueiri MB, Tu SM, Yu-Lee LY, Lin SH. The central role of osteoblasts in the metastasis of prostate cancer. Cancer Metastasis Rev 2006;25:601-9.
6. Cicek M, Oursler MJ. Breast cancer bone metastasis and current small therapeutics. Cancer Metastasis Rev 2006;25:635-44.
7. Weilbaecher KN, Guise TA, McCauley LK. Cancer to bone: a fatal attraction. Nat Rev Cancer 2011;11:411-25.
8. Goel HL, Li J, Kogan S, Languino LR. Integrins in prostate cancer progression. Endocr Relat Cancer 2008;15:657-64.
9. Bisanz K, Yu J, Edlund M, Spohn B, Hung MC, Chung LW, et al. Targeting ECM-integrin interaction with liposome-encapsulated small interfering RNAs inhibits the growth of human prostate cancer in a bone xenograft imaging model. Mol Ther 2005;12:634-43.
10. Hall CL, Dai J, van Golen KL, Keller ET, Long MW. Type I collagen receptor (a2b1) signaling promotes the growth of human prostate cancer cells within the bone. Cancer Res 2006;66:8648-54.
11. McCabe NP, De S, Vasanji A, Brainard J, Byzova TV. Prostate cancer specific integrin avb3 modulates bone metastatic growth and tissue remodeling. Oncogene 2007;26:6238-43.
12. Ports MO, Nagle RB, Pond GD, Cress AE. Extracellular engagement of a6 integrin inhibited urokinase-Type plasminogen activator-mediated cleavage and delayed human prostate bone metastasis. Cancer Res 2009;69:5007-14.
13. Yang GY, Xu KS, Pan ZQ, Zhang ZY, Mi YT, Wang JS, et al. Integrin avb6 mediates the potential for colon cancer cells to colonize in and metastasize to the liver. Cancer Sci 2008;99:879-87.
14. Breuss JM, Gallo J, DeLisser HM, Klimanskaya IV, Folkesson HG, Pittet JF, et al. Expression of the b6 integrin subunit in development, neoplasia and tissue repair suggests a role in epithelial remodeling. J Cell Sci 1995;108(Pt 6):2241-51.
15. Azare J, Leslie K, Al-Ahmadie H, Gerald W, Weinreb PH, Violette SM, et al. Constitutively activated Stat3 induces tumorigenesis and enhances cell motility of prostate epithelial cells through integrin b6. Mol Cell Biol 2007;27:4444-53.
16. Van Aarsen LA, Leone DR, Ho S, Dolinski BM,McCoon PE, LePage DJ, et al. Antibody-mediated blockade of integrin avb6 inhibits tumor progression in vivo by a transforming growth factor-b-regulated mechanism. Cancer Res 2008;68:561-70.
17. Sheppard D. In vivo functions of integrins. Matrix Biology 2000;19: 203-9.
18. Garlick DS, Li J, Sansoucy B, Wang T, Griffith L, FitzGerald TJ, et al. avb6 Integrin expression is induced in the POET and PTENpc/ mouse models of prostatic inflammation and prostatic adenocarcinoma. Am J Transl Res 2012;4:165-74.
19. Weinreb PH, Simon KJ, Rayhorn P, Yang WJ, Leone DR, Dolinski BM, et al. Function-blocking integrin avb6 monoclonal antibodies: distinct ligand-mimetic and nonligand-mimetic classes. J Biol Chem 2004; 279:17875-87.
20. Fornaro M, Tallini G, Zheng DQ, Flanagan WM, Manzotti M, Languino LR. p27(kip1) acts as a downstream effector of and is coexpressed with the b1C integrin in prostatic adenocarcinoma. J Clin Invest 1999; 103:321-9.
21. Farabaugh SM, Micalizzi DS, Jedlicka P, Zhao R, Ford HL. Eya2 is required to mediate the pro-metastatic functions of Six1 via the induction of TGF-b signaling, epithelial-mesenchymal transition, and cancer stem cell properties. Oncogene 2012;31:552-62.
22. Vidal M, Salavaggione L, Ylagan L, Wilkins M, Watson M, Weilbaecher K, et al. A role for the epithelial microenvironment at tumor boundaries: evidence from Drosophila and human squamous cell carcinomas. Am J Pathol 2010;176:3007-14.
23. Akech J, Wixted JJ, Bedard K, van der Deen M, Hussain S, Guise TA, et al. Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. Oncogene 2010;29:811-21.
24. Franco OE, Jiang M, Strand DW, Peacock J, Fernandez S, Jackson RSII, et al. Altered TGF-beta signaling in a subpopulation of human stromal cells promotes prostatic carcinogenesis. Cancer Res 2011; 71:1272-81.
25. Trerotola M, Jernigan DL, Liu Q, Siddiqui J, Fatatis A, Languino LR. Trop-2 promotes cancer metastasis by modulating b1 integrin functions. Cancer Res 2013;73:3155-67.
26. Goel HL, Fornaro M, Moro L, Teider N, Rhim JS, King M, et al. Selective modulation of type 1 insulin-like growth factor receptor signaling and functions by b1 integrins. J Cell Biol 2004;166:407-18.
27. Chantrain CF, Shimada H, Jodele S, Groshen S, Ye W, Shalinsky DR, et al. Stromal matrix metalloproteinase-9 regulates the vascular architecture in neuroblastoma by promoting pericyte recruitment. Cancer Res 2004;64:1675-86.
28. Pratap J, Wixted JJ, Gaur T, Zaidi SK, Dobson J, Veeraraj KD, et al. Runx2 transcriptional activation of indian hedgehog and a downstream bone metastatic pathway in breast cancer cells. Cancer Res 2008; 68:7795-802.
29. Pratap J, Javed A, Languino LR, van Wijnen AJ, Stein JL, Stein GS, et al. The Runx2 osteogenic transcription factor regulates matrix metalloproteinase 9 in bone metastatic cancer cells and controls cell invasion. Mol Cell Biol 2005;25:8581-91.
30. Sangaletti S, Di Carlo E, Gariboldi S, Miotti S, Cappetti B, Parenza M, et al. Macrophage-derived SPARC bridges tumor cell-extracellular matrix interactions toward metastasis. Cancer Res 2008;68: 9050-9.
31. Khosla S, Westendorf JJ, Oursler MJ. Building bone to reverse osteoporosis and repair fractures. J Clin Invest 2008;118:421-8.
32. Cooper CR, Chay CH, Pienta KJ. The role of avb3 in prostate cancer progression. Neoplasia 2002;4:191-4.
33. Akhtari M, Mansuri J, Newman KA, Guise TM, Seth P. Biology of breast cancer bone metastasis. Cancer Biol Ther 2008;7:3-9.
34. Sottnik JL, Hall CL, Zhang J, Keller ET. Wnt and Wnt inhibitors in bone metastasis. Bonekey Rep 2012;1:1-7.
35. Monroe DG, McGee-Lawrence ME, Oursler MJ, Westendorf JJ. Update on Wnt signaling in bone cell biology and bone disease. Gene 2012;492:1-18.
36. Pratap J, Akech J, Wixted JJ, Szabo G, Hussain S, McGee-Lawrence ME, et al. The histone deacetylase inhibitor, vorinostat, reduces tumor growth at the metastatic bone site and associated osteolysis, but promotes normal bone loss. Mol Cancer Ther 2010;9:3210-20.
37. Zhang X, Morrissey C, Sun S, Ketchandji M, Nelson PS, True LD, et al. Androgen receptor variants occur frequently in castration resistant prostate cancer metastases. PLoS ONE 2011;6:e27970.
38. Yin JJ, Mohammad KS, Kakonen SM, Harris S, Wu-Wong JR, Wessale JL, et al. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci U S A 2003;100: 10954-9.
39. Li ZG, Mathew P, Yang J, Starbuck MW, Zurita AJ, et al. Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. J Clin Invest 2008;118: 2697-710.
40. Ahmed N, Pansino F, Baker M, Rice G, Quinn M. Association between avb6 integrin expression, elevated p42/44 kDa MAPK, and plasminogen-dependent matrix degradation in ovarian cancer. J Cell Biochem 2002;84:675-86.
41. Morgan MR, Thomas GJ, Russell A, Hart IR, Marshall JF. The integrin cytoplasmic-Tail motif EKQKVDLSTDC is sufficient to promote tumor cell invasion mediated by matrix metalloproteinase (MMP)-2 or MMP-9. J Biol Chem 2004;279:26533-9.
42. Kawamata H, Nakashiro K, Uchida D, Harada K, Yoshida H, Sato M. Possible contribution of active MMP2 to lymph-node metastasis and secreted cathepsin L to bone invasion of newly established human oral-squamous-cancer cell lines. Int J Cancer 1997;70:120-7.
43. Corey E, Brown LG, Quinn JE, Poot M, Roudier MP, Higano CS, et al. Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res 2003; 9:295-306.
44. Nemeth JA, Yousif R, Herzog M, Che M, Upadhyay J, Shekarriz B, et al. Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis. J Natl Cancer Inst 2002;94:17-25.
45. Trudel D, Fradet Y, Meyer F, Harel F, Tetu B. Significance of MMP-2 expression in prostate cancer: an immunohistochemical study. Cancer Res 2003;63:8511-5.
46. Thiolloy S, Edwards JR, Fingleton B, Rifkin DB, Matrisian LM, Lynch CC. An osteoblast-derived proteinase controls tumor cell survival via TGF-b activation in the bone microenvironment. PLoS ONE 2012;7: e29862.
47. Mosig RA, Dowling O, DiFeo A, Ramirez MC, Parker IC, Abe E, et al. Loss of MMP-2 disrupts skeletal and craniofacial development and results in decreased bone mineralization, joint erosion and defects in osteoblast and osteoclast growth. Hum Mol Genet 2007;16: 1113-23.
48. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010;375:1437-46.
49. Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, Girard OM, et al. Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell 2009;16:510-20.